OBJECTIVE: Matrix metalloproteinase-9 (MMP9) is a protease associated with degradation of collagen and elastin. Because increased MMP9 activity in vaginal tissue has been associated with pelvic organ prolapse (POP), we sought to comprehensively estimate MMP9 genetic variants and the risk for advanced prolapse. METHODS: This is a candidate gene association study of women with stage III-IV prolapse (case group, n=239) and women with stage 0-1 prolapse (control group, n=197). We attempted to oversample "extreme" phenotypes, including younger women with severe prolapse and older women without prolapse, in an attempt to concentrate the genetic effect. We used a linkage disequilibrium tagged approach to identify single nucleotide polymorphisms in MMP9 to evaluate in our study. To minimize potential confounding by race, our analysis focused on non-Hispanic white women. We performed multivariable logistic regression to estimate the association between MMP9 single nucleotide polymorphisms and case-control status, adjusting for age and vaginal parity. RESULTS: Women with advanced prolapse were slightly younger (64.8 ± 10.3 compared with 69.0 ± 10.2 years, P<.001) and more likely to have had one or more vaginal deliveries (96.6% compared with 82.2%, P<.001) when compared with control participants. Eight single nucleotide polymorphisms were assessed, which represented 93% coverage of the MMP9 gene. Of these, two were associated with advanced prolapse: 1) rs3918253 (adjusted odds ratio [OR] 0.64, 95% confidence interval [CI] 0.41-1.0, P=.05); and 2) rs3918256 (adjusted OR 0.64, 95% CI 0.41-1.01, P=.05). CONCLUSION: MMP9 is a biologically plausible candidate gene for POP given our results.
OBJECTIVE:Matrix metalloproteinase-9 (MMP9) is a protease associated with degradation of collagen and elastin. Because increased MMP9 activity in vaginal tissue has been associated with pelvic organ prolapse (POP), we sought to comprehensively estimate MMP9 genetic variants and the risk for advanced prolapse. METHODS: This is a candidate gene association study of women with stage III-IV prolapse (case group, n=239) and women with stage 0-1 prolapse (control group, n=197). We attempted to oversample "extreme" phenotypes, including younger women with severe prolapse and older women without prolapse, in an attempt to concentrate the genetic effect. We used a linkage disequilibrium tagged approach to identify single nucleotide polymorphisms in MMP9 to evaluate in our study. To minimize potential confounding by race, our analysis focused on non-Hispanic white women. We performed multivariable logistic regression to estimate the association between MMP9 single nucleotide polymorphisms and case-control status, adjusting for age and vaginal parity. RESULTS:Women with advanced prolapse were slightly younger (64.8 ± 10.3 compared with 69.0 ± 10.2 years, P<.001) and more likely to have had one or more vaginal deliveries (96.6% compared with 82.2%, P<.001) when compared with control participants. Eight single nucleotide polymorphisms were assessed, which represented 93% coverage of the MMP9 gene. Of these, two were associated with advanced prolapse: 1) rs3918253 (adjusted odds ratio [OR] 0.64, 95% confidence interval [CI] 0.41-1.0, P=.05); and 2) rs3918256 (adjusted OR 0.64, 95% CI 0.41-1.01, P=.05). CONCLUSION:MMP9 is a biologically plausible candidate gene for POP given our results.
Authors: F Chiaffarino; L Chatenoud; M Dindelli; M Meschia; A Buonaguidi; F Amicarelli; M Surace; E Bertola; E Di Cintio; F Parazzini Journal: Eur J Obstet Gynecol Reprod Biol Date: 1999-01 Impact factor: 2.435
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson Journal: Am J Hum Genet Date: 2003-12-15 Impact factor: 11.025
Authors: Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2005-10-23 Impact factor: 38.330
Authors: Hong Xu; Simon G Gregory; Elizabeth R Hauser; Judith E Stenger; Margaret A Pericak-Vance; Jeffery M Vance; Stephan Züchner; Michael A Hauser Journal: Bioinformatics Date: 2005-09-22 Impact factor: 6.937
Authors: Kimberly S McMillan; Sam Siddighi; Jeffrey S Hardesty; Joshua J Yune; Philip J Chan Journal: Int Urol Nephrol Date: 2014-09-14 Impact factor: 2.370
Authors: Jennifer M Wu; Renée M Ward; Kristina L Allen-Brady; Todd L Edwards; Peggy A Norton; Katherine E Hartmann; Elizabeth R Hauser; Digna R Velez Edwards Journal: Am J Obstet Gynecol Date: 2012-11-27 Impact factor: 8.661
Authors: Renée M Ward; Digna R Velez Edwards; Todd Edwards; Ayush Giri; Rebecca N Jerome; Jennifer M Wu Journal: Am J Obstet Gynecol Date: 2014-04-12 Impact factor: 8.661
Authors: Rufus Cartwright; Anna C Kirby; Kari A O Tikkinen; Altaf Mangera; Gans Thiagamoorthy; Prabhakar Rajan; Jori Pesonen; Chris Ambrose; Juan Gonzalez-Maffe; Phillip Bennett; Tom Palmer; Andrew Walley; Marjo-Riitta Järvelin; Chris Chapple; Vik Khullar Journal: Am J Obstet Gynecol Date: 2014-08-08 Impact factor: 8.661
Authors: Maryam B Khadzhieva; Dmitry S Kolobkov; Svetlana V Kamoeva; Anastasia V Ivanova; Serikbay K Abilev; Lyubov E Salnikova Journal: Biomed Res Int Date: 2015-08-10 Impact factor: 3.411
Authors: Kathleen Chin; Cecilia Wieslander; Haolin Shi; Sunil Balgobin; T Ignacio Montoya; Hiromi Yanagisawa; R Ann Word Journal: PLoS One Date: 2016-04-28 Impact factor: 3.240
Authors: Ayush Giri; Jennifer M Wu; Renee M Ward; Katherine E Hartmann; Amy J Park; Kari E North; Mariaelisa Graff; Robert B Wallace; Gihan Bareh; Lihong Qi; Mary J O'Sullivan; Alexander P Reiner; Todd L Edwards; Digna R Velez Edwards Journal: PLoS One Date: 2015-11-06 Impact factor: 3.240